Document is current
Any future updates will be listed below
-
Authors
Apjok, Gábor https://orcid.org/0000-0002-8627-2378
Számel, Mónika
Christodoulou, Chryso
Seregi, Viktória
Vásárhelyi, Bálint Márk
Stirling, Tamás https://orcid.org/0000-0002-8964-6443
Eszenyi, Bálint
Sári, Tóbiás
Vidovics, Fanni
Nagrand, Erika
Kovács, Dorina
Szili, Petra
Lantos, Ildikó Ilona
Méhi, Orsolya
Jangir, Pramod K. https://orcid.org/0000-0001-8330-0655
Herczeg, Róbert
Gálik, Bence https://orcid.org/0000-0002-3949-7005
Urbán, Péter
Gyenesei, Attila
Draskovits, Gábor
Nyerges, Ákos https://orcid.org/0000-0002-1581-490X
Fekete, Gergely
Bodai, László https://orcid.org/0000-0001-8411-626X
Zsindely, Nóra https://orcid.org/0000-0002-6189-3100
Dénes, Béla https://orcid.org/0000-0002-9889-529X
Yosef, Ido
Qimron, Udi
Papp, Balázs
Pál, Csaba https://orcid.org/0000-0002-5187-9903
Kintses, Bálint https://orcid.org/0000-0003-0844-0310
- License Information
-
More Information
Article History
Received: 26 November 2021
Accepted: 4 January 2023
First Online: 9 February 2023
Competing interests
: G.A., M.S., T.Sári, O.M., U.Q. and B.K. are inventors on a filed patent application of DEEPMINE (European Patent Office). The Biological Research Center Szeged holds an active patent on DIVERGE (PCT/EP2017/082574, US 10,669,537 B2, European Patent No. 3526327), where B.K. and C.P. are inventors. U.Q. is the Chief Technology Officer of Trobix Innovation Ltd. and is an inventor of a pending patent application on a method to generate bacteriophage variants having extending host ranges (PCT/IL2017/050734). All other authors have no competing interests.
